renal cell carcinoma

Biotech

Instil Bio takes the ax to its lead asset, cuts 60% of its staff

Instil Bio is trekking through rocky terrain, culling its lead asset and cutting 60% of its staff as it tries to instill confidence in a new path.
Max Bayer Dec 8, 2022 10:24am

FDA sinks Allarity’s plans for lead oncology asset

Aug 2, 2022 2:41pm

Despite 0% response rate, 4D hits primary goal in cancer trial

Mar 23, 2022 7:45am

FDA allows Allogene to resume CAR-T trials after safety scare

Jan 10, 2022 10:16am

Chasing Merck, Arrowhead posts early data on anti-cancer RNAi

Jul 7, 2021 9:00am

Calithera flunks phase 2 cancer trial, axes 35% of staff

Jan 4, 2021 8:23am